|
Ivabradine (INN) is a novel medication used for the symptomatic management of stable angina pectoris. It is marketed by Servier under the trade names Corlanor (United States), Procoralan (worldwide), Coralan (in Hong Kong, Singapore, Australia and some other countries), Corlentor (in Armenia, Spain, Italy and Romania) and Coraxan (in Russia and Serbia). It is also marketed in India under the brand names Ivabid and Bradia. During its development, ivabradine was known as S-16257. Ivabradine acts by reducing the heart rate via specific inhibition of the funny channel, a mechanism different from that of beta blockers and calcium channel blockers, two commonly prescribed antianginal drugs. Ivabradine is a cardiotonic agent. ==Medical uses== Ivabradine was approved by the European Medicines Agency in 2005 and by the United States Food and Drug Administration in 2015. It is indicated for the symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm who cannot take beta blockers. It is also indicated in combination with beta blockers in heart failure patients with LVEF lowers than 35 percent inadequately controlled by beta blockers alone and whose heart rate exceeds 70 beats per minute. It has been shown to be as effective as the beta blocker atenolol and comparable with amlodipine in the management of chronic stable angina. Apart from angina, it is also being used off-label in the treatment of inappropriate sinus tachycardia. An Italian clinical study showed significant improvement of symptoms with ivabradine compared to placebo in individuals with inappropriate sinus tachycardia.〔Cappato R, Castelvecchio S.Clinical Efficacy of Ivabradine in Patients With Inappropriate Sinus Tachycardia. A Prospective, Randomized, Placebo-Controlled, Double-Blind, Crossover Evaluation Journal of the American College of Cardiology. 2012;60:1323-9.〕 Ivabradine can possibly be used in reducing the heart rate in patients with sepsis or septic shock, along with supportive care like fluids, vasopressors, and broad spectrum antibiotics.〔Nair AS, Gopal T. Ivabradine in sepsis . J Anaesthesiol Clin Pharmacol (online ) 2013 (2014 Jun 17 );29:570-1. Available from: http://www.joacp.org/text.asp?2013/29/4/570/119154〕 Adding ivabradine to heart failure medication decreases both cardiovascular death rate and risk of hospitalization for heart failure. In some countries, ivabradine was approved for the treatment of chronic heart failure with systolic dysfunction in patients with sinus rhythm and whose heart rate is ≥70 bpm. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Ivabradine」の詳細全文を読む スポンサード リンク
|